Daniel J Song, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1650 Cochrane Cir Unit Meddac, Fort Carson, CO 80913 Phone: 719-526-7440 |
Ryan Bucknam, M.D. Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 1650 Cochrane Cir, Fort Carson, CO 80913 Phone: 719-526-2273 |
Nathan Andrew Franklin, D.O. Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 1650 Cochrane Cir Unit Meddac, Fort Carson, CO 80913 Phone: 719-526-7440 |
Jacob Arthur, M.D. Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 1650 Cochrane Cir Rm 3100, Fort Carson, CO 80913 Phone: 719-526-7440 |
News Archive
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.
For older adults, dry mouth can be a common side effect of prescribed medications. Having dry mouth means you don't have enough saliva, or spit, to keep your mouth wet. The condition can lead to problems chewing, eating, swallowing, and even talking. What's more, dry mouth puts you at higher risk for tooth decay and oral infections.
But a new study by researchers at Loyola University Health System and other centers casts doubt on the TB spore theory. Researchers were unable to detect spores in TB cultures and demonstrated that the TB bacterium doesn't even contain genes related to those needed to produce spores. Researchers also failed to find any spores in frogs infected with TB bacteria, which would have been expected if TB bacteria produced spores in the course of infection.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
› Verified 9 days ago